CPA remains unwavering in our commitment to rebuilding U.S. industry and supporting American workers. China’s latest move only proves that our efforts are making an impact—and we will not back down.
The United States is amid a dangerous drug shortage that endangers patients, undermines our health care system and exposes a deep vulnerability to national security. America’s overwhelming reliance on foreign manufacturers for generic drugs is at the center of it.
The Trump administration’s decision to impose a permanent 10% baseline tariff on imports from all countries, combined strategically with higher reciprocal tariffs on nations engaging in unfair trade practices, marks a crucial step forward in reindustrializing America and restoring economic strength and security.
The stock market is not the economy, and it certainly isn’t a proxy for the health of U.S. manufacturing or working-class prosperity.
The NTE report specifically identifies significant barriers and illicit trade practices, particularly involving China, impacting the solar, automotive, and steel industries, underscoring the urgent need for robust U.S. enforcement to address transshipment and tariff evasion.
As the United States looks to compete in these advanced industries, it’s important to remember the two building blocks that undergird them: Steel and aluminum.
CPA’s new Trade Issues and Tariff Recommendation Tracker highlights specific tariff recommendations that will produce near-term wins.
In a comment letter submitted to USTR in response to the Section 301 investigation, CPA highlighted China’s extensive use of state-driven subsidies and unfair trade practices, urging immediate implementation of targeted measures to support the revitalization of the U.S. shipbuilding industry.
Strong federal investment in the National Science Foundation and National Institutes of Health is vital for American innovation, economic growth, and national security.
For years, the de minimis loophole has flooded the U.S. with uninspected, untaxed, and often dangerous goods—from counterfeit products to fentanyl precursors fueling America’s opioid crisis.
